 Good evening everyone, this is a real honour, applied probably four times out of last six years, so this is the first time I've got something, so I'm very very excited. So thank you to the committee, to the sponsors, to the donors particularly to the North West Committee up in Tamworth, I think this is very generous considering the conditions out in the country at the moment are tough, so their generosity is very much appreciated. So for our work, I work with Professor Studley at Macquarie University and our work aims to develop new treatments for patients that have brain arteriovenous malformations, a bit of a mouthful so we call them AVMs. So these are blood vessel malformations that can occur in the brain, they're particularly prone to rupture causing stroke. Now unlike age-associated stroke, this occurs in children and young people so it can be particularly devastating for these young individuals and their families. There are some treatments, they can be cured by surgery, also by radiation, but this is inappropriate and risky for probably a third of these AVM patients, so they remain at risk of stroke. So to fill this gap, our aim is to develop a vascular targeting approach to treatment. And this is really where we deliver a drug through the bloodstream that can target to the AVMs and cause their blockage. But the key is how do we target these drugs to the AVMs, what makes them different. And we didn't really have a clue until last year and some studies out of the US showed that these AVMs or the majority of them have a mutation in these genes called RAZ. So they're often common in cancer but not found before in vascular cells. So these RAZ mutations actually cause a lot of molecular changes within these cells and this is really exciting because now we have a way we can develop a cell model in the laboratory and study the phenotype of these cells and the molecular changes. So for us that means we can potentially find a target on the surface of these cells so we can direct these drugs to the AVM specifically. So the kind donation of this funding allows us to develop this cell model in the laboratory this year and also to then analyze these molecularly fine targets on the surface and as well we're going to use the novel way of developing molecules that can deliver the drugs, these are called DNA actimers and that's sort of beyond the three minutes that I've got here but please come and speak to me later about them. But again the hope that this is the start of developing some new treatments for these young vulnerable patients and again eternally grateful to the Brain Foundation for this funding. Thank you.